How important are carbohydrates for injectable use in Europe?
When manufacturing large-volume parenteral preparations, such as parenteral nutrition or dialysis preparations, as well as
injection preparations used solely as nutrient or as a vehicle for ethical drugs (medicinal products delivered under prescription),
carbohydrates are essential. Carbohydrates, such as glucose, are the main source of energy for body cells. Although most body
cells can utilise fats for energy in a pinch, brain cells and red blood cells rely almost completely on glucose to fulfil
their energy needs. Glucose, the main type of carbohydrates used in parenteral preparations, is considered a life-saving molecule
because it is used as first-line treatment in emergency situations that lead to dehydration and acute hypoglycaemia.
Manufacturing carbohydrates-based parenteral preparations requires highly controlled APIs. Parenteral preparations are sterile
drug products and their manufacturing conditions are subjected to strict requirements and standards, including a high level
of microbial and physiochemical quality for raw materials APIs. Inferior quality of such APIs can jeopardise the entire parenteral
drug, with a serious impact on patient safety.
Injectable solutions prepared with carbohydrates are used on a mass scale in hospitals and other healthcare settings, but
are often taken for granted because they are expected to be available everywhere and at the highest quality. For manufacturers,
however, these specialised ingredients are small scale compared with the wider portfolio of products and other applications
from the starch biorefinery industry, such as food, feed nutrition, chemical and industrial applications. In addition, organic
growth is limited; in Europe, access to healthcare is ensured for all the population regardless of social status or age. Even
though the extension of life is obvious in Europe, the spread of access to healthcare counterbalance any substantial organic
What are the main challenges associated with manufacturing carbohydrates for injection?
Health suppliers, hospitals and clinics regard carbohydrates for injection as commodities and, as such, they are a preferred
target for price reductions, which makes it a challenging area for manufactures to invest in. In addition, manufacturers face
continually evolving regulations and quality standards; for example, implementation of the ICH Q9 and Q11 guidelines and the
recently adopted EC Directive on Falsified Medicinal Products (amending Directive 2001/83/EC) will require manufacturers to
reinforce their existing quality management system even further. Finally, because carbohydrates for injectbale use are commonly
processed from natural origin raw materials (such as cereals), their production requires sophisticated and well controlled
processes and purification steps.
Considering the challenges in injectable carbohydrate manufacture, why did Roquette decide to invest in this niche market?
We have invested in this market by creating a new injectable carbohydrate facility in Lestrem (France). Such a niche market
is a challenging environment for investment, but Roquette however, decided to proceed with the investment as part of its
long term strategy to remain a responsible supplier in this demanding field. In fact, Roquette has pioneered the development
of glucose grades for the preparation of injectable and dialysis solutions over many decades and is the leader in the manufacturing
of such carbohydrates in Europe.
This leadership position comes with a sense of corporate responsibility to ensure the continuity of these vital products and
this in turn has lead to continuous investment.
How are difficulties in the supply chain managed and accounted for to ensure an uninterrupted supply of these crucial medicines?
Supply chain continuity is a critical issue for carbohydrates for injectable use because of their criticality in healthcare
settings. Any disruption in the supply chain could lead to shortages, which would endanger patients. Supply chain difficulties
can be managed by implementing a solid business continuity plan; indeed, ensuring supply chain continuity should be a key
part of such a plan. At our company, we use several production sites to help ensure production continuity. For example, our
glucose production facility in the US can act as a back up to international supply.
It is also important to have reliable supply chain and distribution networks that ensure the traceability and the continuity
of supply. Less players in supply chain, to some extent, equals less vulnerability, However, it is always important to verify
that all supply-chain players have a quality management system in place to ensure traceability and action plans for the continuity